Targeting Leukotrienes in Kidney Disease

Inclusion Criteria: * CKD stage 3 * urine albumin to creatinine ratio 200-5000 mg/g * blood pressure \<140/90 mmHg * use of angiotensin converting enzyme inhibitor or angiotensin receptor blocker with stable dose for 4 weeks * history of diabetes type 1 or 2 * BMI \<40 kg/m2 * Stable antihypertensive regimen for at least one month prior to enrollment * Stable diabetes regimen for at least one month prior to enrollment * Sedentary or recreationally active (\<2 days of vigorous aerobic exercise as vigorous exercise may affect vascular function measurements) * Able to provide consent Exclusion Criteria: * Significant comorbid conditions that lead the investigator to conclude that life expectancy is less than 1 year * Uncontrolled hypertension * Factors judged to limit adherence to interventions (e.g. history of medication noncompliance, noncompliance with follow up visits, significant cognitive impairment, etc.) * Anticipated initiation of dialysis or kidney transplantation within 3 months * Current participation in another research study * Pregnancy or planning to become pregnant or currently breastfeeding * Allergy to aspirin * Severe hepatic impairment (Child-Pugh Class C) * History of major psychiatric disorder * Use of inhaled or systemic corticosteroids or long-acting beta agonists (higher risk of neuropsychiatric reaction) * Current use of SGLT2 inhibitor * Current use of phenobarbital, rifampin or carbamazepine.